Aimed Alliance Comments on 2027 NBPP
On March 13, 2026, Aimed Alliance commented on the 2027 Notice of Benefit and Payment Parameters (2027 NBPP). In its…
Browsing: Drug Pricing
Aimed Alliance Provides Testimony of UPLs Before New Jersey’s PDAC
On March 19, 2026, Aimed Alliance provided testimony to the New Jersey Prescription Drug Affordability Council, which is developing legislative…
Aimed Alliance Pushes Back on PDAB Legislation in Illinois
On March 18, 2026, Aimed Alliance submitted comments to the Health Care Availability & Accessibility Committee urging caution against Illinois…
Aimed Alliance Urges Amendments to Virginia’s PDAB Bill to Protect Patient Access
On March 13, 2026, Aimed Alliance sent a letter to Governor Abigail Spanberger urging amendments to Virginia’s House Bill 483,…
Administration Targets Foreign Drug Pricing in Upcoming Section 301 Investigation
Recently, the Trump Administration announced plans to initiate a new Section 301 investigation into foreign drug pricing policies, which it…
Minnesota Reports $1.34 Billion in 340B Revenue
Minnesota’s second year of 340B reporting shows that Covered Entities generated at least $1.34 billion in net 340B revenue in…
Aimed Alliance Urges Maryland PDAB to Protect Patient Access in UPL Deliberations
Aimed Alliance sent letters to the Maryland PDAB urging it to proceed cautiously with setting a UPL for Jardiance and…
GLOBE Model Expected to Have Minimal Impact on Part B OOP Costs
A new analysis published by Avalere Health found that the proposed GLOBE (Global Benchmark for Efficient Drug Pricing) Model would have…
New Report – International Reference Pricing: Lessons Learned from Abroad
For decades, rising costs of health care, health insurance, and prescription drugs have been a major concern for American consumers, caregivers,…
Aimed Alliance Urges Reconsideration of VA PDAB Bill
Aimed Alliance recently sent a letter urging the Virginia House Labor and Commerce Committee to reconsider House Bill 483, which…